R&D channel feed

Tout­ing PhI­II suc­cess for arthri­tis drug Taltz, Eli Lil­ly chas­es ri­val No­var­tis in heat­ed im­munol­o­gy race

7 years ago

Sar­co­ma ex­pert George Demetri grades the lat­est state­ment on Nanobi­otix's late-stage drug NBTXR3

7 years ago
People
Pharma

Lit­tle Ar­sa­nis steers its on­ly clin­i­cal-stage ther­a­py to the scrap heap af­ter a PhII im­plo­sion

7 years ago

C-Bridge hands Nu­ance Biotech $35M, open­ing doors to more Chi­na li­cens­ing deals

7 years ago
Financing
China

Pos­i­tive piv­otal da­ta in hand, GBT is hus­tling to the FDA in search of a quick OK for sick­le cell drug -- but that's no easy task

7 years ago

Sum­mit ex­ecs sharp­en the bud­get ax as Duchenne MD study flops — shares rout­ed at Sarep­ta part­ner

7 years ago

With the ink on their $25M Astel­las deal still dry­ing, Aquinox shares get blast­ed on PhI­II fail­ure

7 years ago

As­traZeneca, Mer­ck score a block­buster ad­vance as Lyn­parza comes through in front­line ovar­i­an can­cer

7 years ago

Pain Ther­a­peu­tics en­dures yet an­oth­er FDA slap­down on Re­moxy — time to call it quits?

7 years ago

Roivant un­der­goes ma­jor re­struc­tur­ing, cut­ting and shift­ing its staff

7 years ago
Startups
Pharma

Brain­storm backs off a con­tro­ver­sial plan to sell its ex­per­i­men­tal ALS med, but this is­sue is far from over

7 years ago

Oops. Pfiz­er's CDK 4/6 block­buster Ibrance flunks the OS mark for breast can­cer

7 years ago

Sud­den death forces Sophiris to halt fol­lowup ther­a­py in prostate can­cer study — shares crushed

7 years ago

Pan­cre­at­ic can­cer study fail­ure crip­ples a Mer­ri­mack drug, forc­ing a coup de grâce and pipeline re­treat

7 years ago

Af­ter Ro­va-T bust, Ab­b­Vie plans new sol­id tu­mor as­sault, li­cens­ing next-gen CAR-T tech from Cal­i­br

7 years ago
Discovery

Roche’s Tecen­triq scoops up a big win in small cell lung can­cer, grab­bing the lead in front­line cas­es

7 years ago

Boehringer backs €20B R&D game plan with a $272M blue­print for new fa­cil­i­ty — 100 new hires

7 years ago
Financing

J&J opens up a new biotech in­cu­ba­tor, pol­ish­ing the Big Ap­ple's am­bi­tions to cre­ate a ma­jor hub

7 years ago
Startups
Pharma

Lat­est rank­ing of top re­search in­sti­tu­tions show Chi­na com­ing on strong — with sig­nif­i­cant im­pli­ca­tions for biotech

7 years ago
China

On a win­ning streak, Heron rock­ets up 30% on PhI­Ib pain drug da­ta

7 years ago

Mauled by a ma­jor set­back, In­cyte is point­ing to a bet­ter fu­ture — but con­cedes it al­so had to scrap an­oth­er failed study

7 years ago

No­vo Nordisk’s 'se­ma' whips Mer­ck’s di­a­betes drug ri­val in PhI­II as it reach­es for best-in-class rank­ing for GLP-1 group

7 years ago

Step right up: A biotech may soon sell an ex­per­i­men­tal med to dy­ing ALS pa­tients un­der 'Right to Try'

7 years ago
Bioregnum
Opinion

Bio­phar­ma ri­vals at Roche and Bay­er both stand to ben­e­fit from the trend to­ward in­creased test­ing of can­cer pa­tients

7 years ago
First page Previous page 268269270271272273274 Next page Last page
A service from the Financial Times